Clinical trials: HPV Cancers
Patient Adherence
Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project)
Background: Cervical cancer is one of the leading causes of cancer death among women worldwide, with more than 85% of cases occurring in low- and middle-income countries.
- Trial name
- ATICA (NCT03478397)
- Testing
- Multicomponent mHealth Intervention
- Where
- Argentina
- Volunteers
- 5,389 people
- Sponsor
- Centro de Estudio de Estado y Sociedad
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Background: Human papillomavirus (HPV) can cause vulvar high-grade squamous intraepithelial lesions (HSIL). Sometimes, this can become cancer. Researchers want to see if T cell therapy can treat vulvar HSIL.
- Conditions
- Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
- Trial name
- NCT03937791
- Testing
- E7 T Cell Receptor (TCR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
HPV
Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy
This study seeks to compare the accuracy and acceptability of HPV testing self-sampling kit and standard clinician-sampling for HPV testing.
- Trial name
- NCT04585243
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Milton S. Hershey Medical Center
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Genital Warts
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or…
- Trial name
- TheraVACCS (NCT02750202)
- Testing
- Quadrivalent HPV vaccine, Hepatitis B vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Pretoria
Cervical Intraepithelial Neoplasia
Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)
Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal.
- Trial name
- NCT01131312
- Testing
- Thinprep, Hybrid capture 2, Colposcopy
- Where
- 3 sites in United States
- Volunteers
- 5,060 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries.
- Trial name
- NCT00481767
- Testing
- Cervarix
- Where
- 2 sites in Senegal, Tanzania
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Oropharyngeal Squamous Cell Carcinoma
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
In general, patients with Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma (HPVOPC) are curable, young and will live for prolonged periods.
- Trial name
- NCT02072148
- Testing
- PET/CT, Radiotherapy, Concurrent Chemoradiation
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Warts
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN…
- Trial name
- NCT02393417
- Testing
- CANDIN
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nielsen BioSciences, Inc.
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT03258554
- Testing
- Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy
- Where
- 256 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Survivor, Prevention of Human Papillomavirus Infection
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2)…
- Trial name
- NCT01492582
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration
- Where
- 5 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- University of Alabama at Birmingham
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00578227
- Testing
- Cervarix™, Twinrix ™ Paediatric
- Where
- 21 sites in Canada, Denmark and 2 more
- Volunteers
- 814 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Precancerous Condition
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine…
- Trial name
- NCT00513526
- Testing
- Gardasil
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- AIDS Malignancy Consortium
Head and Neck Squamous Cell Carcinoma
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or…
- Trial name
- NCT03389477
- Testing
- Palbociclib, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Infections, Papillomavirus, Papillomavirus Vaccines
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. The current Phase 3b study is designed to assess the immunogenicity and safety of a commercially available vaccine…
- Trial name
- NCT00637195
- Testing
- Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™), Engerix™
- Where
- 2 sites in Belgium
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections, Warts
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
The objective is to conduct a pilot study to determine the effectiveness of PURELL VF481 to treat warts located on the hands.
- Conditions
- Papillomavirus Infections, Warts, Condylomata Acuminata, Epidermodysplasia Verruciformis
- Trial name
- NCT00973856
- Testing
- PURELL VF481
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cleveland Clinic Akron General